PLSH (Panacea Life Sciences Holdings) YoY EBITDA Growth: 97.30% (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Panacea Life Sciences Holdings YoY EBITDA Growth?

Panacea Life Sciences Holdings PLSH YoY EBITDA Growth is 97.30% as of Sep. 2025. The stock has 6 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Panacea Life Sciences Holdings's YoY EBITDA Growth for the quarter that ended in Sep. 2025 was 97.30%.

Panacea Life Sciences Holdings's EBITDA per Share for the three months ended in Sep. 2025 was $-0.00.

Panacea Life Sciences Holdings YoY EBITDA Growth Related Terms

Panacea Life Sciences Holdings YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Panacea Life Sciences Holdings's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panacea Life Sciences Holdings YoY EBITDA Growth Chart

Panacea Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
0.00 -24.21 -205.93 21.05

Panacea Life Sciences Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.34 81.25 169.14 218.42 97.30

Panacea Life Sciences Holdings YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Panacea Life Sciences Holdings's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-0.285--0.361)/ | -0.361 |
=21.05 %

Panacea Life Sciences Holdings's YoY EBITDA Growth for the quarter that ended in Sep. 2025 is calculated as:

YoY EBITDA Growth (Q: Sep. 2025 )
=(EBITDA per Share (Q: Sep. 2025 )-EBITDA per Share (Q: Jun. 2024 )) / | EBITDA per Share (Q: Jun. 2024 )) |
=(-0.001--0.037)/ | -0.037 |
=97.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 97.30% mean?
Panacea Life Sciences Holdings (PLSH) has a YoY EBITDA Growth of 97.30% as of Sep. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Panacea Life Sciences Holdings and its competitors.
Is Panacea Life Sciences Holdings' YoY EBITDA Growth too high?
Panacea Life Sciences Holdings' current YoY EBITDA Growth is 97.30%.
How does Panacea Life Sciences Holdings' YoY EBITDA Growth compare to SHPH and SKYI?
Panacea Life Sciences Holdings' YoY EBITDA Growth of 97.30% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Panacea Life Sciences Holdings and its competitors. Panacea Life Sciences Holdings's current YoY EBITDA Growth is 97.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Life Sciences Holdings stock overvalued right now?
Panacea Life Sciences Holdings (PLSH) has a current YoY EBITDA Growth of 97.30%. The current YoY EBITDA Growth is 97.30%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Panacea Life Sciences Holdings (PLSH), the current YoY EBITDA Growth is 97.30% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Panacea Life Sciences Holdings Business Description

Address 5910 South University Boulevard, C18-193, Greenwood Village, CO, USA, 80121
Panacea Life Sciences Holdings Inc is a holding company organized as a plant-based natural health ingredient and product company, specializing in the development, manufacturing, research, and distribution of products and rapidly growing natural health and wellness market segment for both humans and animals. The company also offers the purest natural remedies within its branded product lines for every aspect of life: PANA Health, PANA Beauty, PANA Sport, PANA Pet, PANA Pure and PANA Life.